Oncotelic Sells CNS/Nasal Tech to Lunai for $12.5M, Targeting Biodefense and Alzheimer’s

Event summary

  • Oncotelic Therapeutics closed a deal with Lunai Bioworks, transferring its N2B nose-to-brain delivery system IP for $12.5M in Series B Convertible Preferred Stock.
  • Lunai gains worldwide rights to the N2B system for biodefense and Alzheimer’s disease applications only.
  • Oncotelic retains control over the technology for other indications, including Parkinson’s and sexual dysfunction.
  • The deal leverages Oncotelic’s biodefense expertise, including leadership with BARDA and DTRA-funded programs.

The big picture

This deal reflects a broader trend of biotech companies monetizing niche delivery technologies to focus on core pipelines. Oncotelic’s move aligns with the growing interest in CNS-targeted therapeutics, particularly in biodefense and neurodegenerative diseases. The $12.5M valuation suggests confidence in the N2B system’s potential, but success will depend on Lunai’s execution in these high-stakes fields.

What we're watching

Biodefense Funding
How Oncotelic will leverage this deal to secure additional government funding (e.g., BARDA, DOD) for biodefense applications.
Alzheimer’s Market
Whether Lunai can successfully develop the N2B system for Alzheimer’s, a highly competitive and capital-intensive space.
Execution Risk
The pace at which Oncotelic can monetize its remaining CNS assets while maintaining strategic control over core oncology and rare disease programs.